Slow, but steady progress. The key highlight for me was work...

Slow, but steady progress. The key highlight for me was work with the FRCBS progressing to phase 2, ie licensing negotiations for ongoing usage of LEAP for exosome purification. This is a great endorsement of LEAP, but of course, will not celebrate till a licencing deal is closed!

Exopharm does seem rightly paranoid on preserving cash and minimising share capital dilution, however I'd still argue that Director's fees should be reduced to 0% (vs current 20% reduction). Also, in this environment, more frequent investor communication is needed - the current communication levels do not help with building market confidence.

Looking forward to what transpires over Q3!